Cisplatin and Etoposide for Colorectal Cancer
Author Information
Author(s): AST Planting, MEL van der Burg, MJ van den Bent, M de Boer-Dennert, G Stoter, J Verweijl
Primary Institution: Rotterdam Cancer Institute/Daniel den Hoed Kliniek
Hypothesis
Can a combination of high-dose cisplatin and oral etoposide be an effective first-line treatment for metastatic colorectal cancer?
Conclusion
The combination of cisplatin and oral etoposide showed minimal activity in treating metastatic colorectal cancer.
Supporting Evidence
- A partial response was observed in two patients with liver metastases.
- Five patients had stable disease.
- Toxicity included anaemia, leucocytopenia, nausea, and vomiting.
Takeaway
Doctors tried a new medicine combination to help people with a type of cancer, but it didn't work very well.
Methodology
Patients received high-dose cisplatin and oral etoposide, with evaluations of response and toxicity.
Limitations
The study had a small sample size and did not show significant benefits from the treatment.
Participant Demographics
14 patients, mostly male, with a median age of 53 years.
Statistical Information
Confidence Interval
95% CI 2-42%
Want to read the original?
Access the complete publication on the publisher's website